Corporate ART Access Programs
PharmAccess HIV Program
Objective
A tribute to Joep Lange’s pioneering work in providing access to antiretroviral treatment in Africa. A 15-year study on clinical outcomes and an additional study on the international policy implications of this work.
Description
The Heineken-PharmAccess HAART program was among the first in Africa to provide antiretroviral treatment in the workplace. Heineken employees and their immediate dependents are eligible for the treatment programme. After 15 years of successful implementation of this program, AIGHD was commissioned to assess the impact of the program, not only on Heineken patients, but also more generally on international policy with respect to engaging the private sector in public sector antiretroviral treatment in Africa: ‘going private to grow public’.
Outcome
1. Scientific research article analyzing the biomedical and clinical results of the program: reaching 90-90-90 objective. 2. Policy paper, describing how the Heineken-PharmAccess approach has influenced international policy on HIV treatment and public-private partnerships. 3. A brochure summarizing the main findings of both papers.Funders
Heineken International
Countries
Nigeria
Rwanda
Burundi
Congo-Brazza
DRC